AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) Meeting Abstract
| Authors: | Chandarlapaty, S.; Linden, H. M.; Neven, P.; Petrakova, K.; Bardia, A.; Kabos, P.; Braga, S.; Boni, V.; Pelekanou, V.; Ternès, N.; Gosselin, A.; Celanovic, M.; Cohen, P.; Paux, G.; Campone, M. |
| Abstract Title: | AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S476 |
| End Page: | S477 |
| Language: | English |
| ACCESSION: | WOS:000700527700243 |
| DOI: | 10.1016/j.annonc.2021.08.547 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 264P -- Source: Wos |
